Subbu Nambi

“On the SEEDS funding, could you provide some additional detail? Is that evenly spread over the course of the program, and is it based on milestones you need to hit, and what's the best use of those funds right now?”

“You have to anticipate more suppliers and adding a series of new assays. There are clearly long-term benefits to these changes. That said, are you contemplating in guidance any potential transitory inefficiencies such as longer turnaround time or a higher failure rates as you migrate assays and evolve menu?”

“As you anticipate an FDA outcome in the fall, where do you think the FDA will focus on, like what type of questions and how are you preparing for those questions?”

“As blood becomes a bigger share of Clonosec volumes and drives more serial testing per patient that you spoke about, especially in surveillance settings with coverage gaps, should reported ASP still be the KPI we anchor on, or is per-patient economics the better lens?”

“Is this driven by new modality or biosimilars? And then And secondly, if our model is right, the partial offset was chromatography. Is there anything interesting to unpack in chromatography?”